Bevacizumab for Metastatic Colorectal Cancer: A Global Cost‐Effectiveness Analysis

BACKGROUND. In the U.S., the addition of bevacizumab to first‐line chemotherapy in metastatic colorectal cancer (mCRC) has been demonstrated to provide 0.10 quality‐adjusted life years (QALYs) at an incremental cost‐effectiveness ratio (ICER) of $571,000/QALY. Due to variability in pricing, value fo...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Goldstein, Daniel A., Chen, Qiushi, Ayer, Turgay, Chan, Kelvin K. W., Virik, Kiran, Hammerman, Ariel, Brenner, Baruch, Flowers, Christopher R., Hall, Peter S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2017
Soggetti:
Health Outcomes and Economics of Cancer Care
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5469597/
https://ncbi.nlm.nih.gov/pubmed/28592621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0455
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi